Results from a randomized, placebo-controlled study indicate that ergocalciferol is safe and effective in delaying the onset of secondary hyperparathyroidism in children with stage 2–3 chronic kidney disease (CKD) and vitamin D deficiency. Nine of 20 children on placebo and three of 20 children on ergocalciferol developed hyperparathyroidism after a median follow-up of 12 months. Normal levels of vitamin D were maintained in 88% of children with stage 2 CKD, but only in 45% of children with stage 3 CKD.
ORIGINAL RESEARCH PAPER
Shroff, R. et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin. J. Am. Soc. Nephrol. doi:10.2215/CJN.04760511
Rights and permissions
About this article
Cite this article
Ergocalciferol delays the onset of secondary hyperparathyroidism in children with chronic kidney disease. Nat Rev Nephrol 8, 192 (2012). https://doi.org/10.1038/nrneph.2012.23
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2012.23